Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 3207 participants.
Also called NCT01609582
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,207 participants
- Sponsor
- Registry
-
NCT01609582 -
2011-001732-37 -
U1111-1129-7824
-
- Other papers using this trial's data
- Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Germany, Hong Kong SAR China, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Ukraine, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01609582. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-08-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
- Condition
- Type 2 Diabetes
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- TAK-875
- Intervention (Drug)
- TAK-875 Placebo
- Lead sponsor
- Takeda
Record details
- Record id
cardio:ct-nct01609582- Content hash
25198101db359c95f8f7706c46d5665ee88f70644e698a0e1965240ab9e5f068